Skip to content

Belgian Pulmonary Function Study

Belgian Pulmonary Function Study : the Belgian Thoracic Society

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01297881
Acronym
BPFS
Enrollment
1000
Registered
2011-02-17
Start date
2011-06-30
Completion date
2012-12-31
Last updated
2013-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Symptoms

Keywords

Caucasian outpatients, undiagnosed respiratory symptoms, dyspnea, cough, sputum

Brief summary

Pulmonary function tests including spirometry, lung volumes, measurements of resistance and diffusing capacity are essential in the diagnosis of several pulmonary diseases. These tests are an integral part of the diagnosis and treatment of lung diseases, but until now there is no clear evidence for the use of many of the pulmonary function tests because of a lack of adequate studies. The obscurity largely pertains to the conditions under which combinations of the various tests are indicated. Therefore the Belgian Thoracic Society, assembling all pulmonologists and the pneumology LOK/GLEMs, will investigate this matter.

Interventions

None listed

Sponsors

Belgian Pulmonary Society
CollaboratorUNKNOWN
Marc Decramer
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Males and females * Age between 18 and 75 years old * New outpatients with respiratory symptoms as dyspnoea, cough, sputum, but without firm diagnosis * Results of the tests are available and acceptable * Standardized list of complaints * Capability of patient for doing pulmonary function tests * Seen by a Pneumologist * Written informed consent

Exclusion criteria

* Patients with diagnosed respiratory disease * Younger than 18 and older than 75 years old * Recent heart attack * Pneumothorax * hemoptoic * Suspicion of Tuberculosis * Not capable to do pulmonary function tests

Design outcomes

Primary

MeasureTime frameDescription
pulmonary function tests (spirometry, volumes, resistance and diffusing capacity in that order) on the preferential diagnosis.end of studyTo determine the effect of stepwise addition of various pulmonary function tests (spirometry, volumes, resistance and diffusing capacity in that order) on the preferential diagnosis and its reflection of the gold standard (final diagnosis), a statistical score will be calculated based on 1/n differential diagnoses after every pulmonary function test. The score will contain corrections for a high number of differential diagnoses and a wrong preferential diagnosis and compared with Linear mixed model after logistic transformation.

Secondary

MeasureTime frameDescription
% correct preferential diagnosesend of studyTo determine the effect of stepwise addition of various pulmonary function tests (spirometry, volumes, resistance and diffusing capacity in that order) on preferential diagnoses and their reflection of the gold standard (final diagnosis), the number and percentage of correct preferential diagnoses will be analysed after every pulmonary function test and compared by a generalized estimating equation model (GEE)
N differential diagnoses in the subgroup with correct preferential diagnosisend of studyTo determine the effect of stepwise addition of various pulmonary function tests (spirometry, volumes, resistance and diffusing capacity in that order) on the number of differential diagnoses and their reflection of the gold standard (final diagnosis), the number of differential diagnoses in patients with correct preferential diagnosis will be analysed after each pulmonary function test and compared with Poisson GEE
subgroup analysesend of studyThe primary endpoint (1/n differntial diagnoses) and 2 secondary endpoints (% correct preferential diagnoses, n differential diagnoses within correct preferential diagnosis) will be analysed in subgroups with final gold standard diagnosis of COPD, asthma, interstitial lung disease and no pulmonary abnormality
Sensitivity analysisend of studyPrimary endpoint (1/n differntial diagnoses) and 2 secondary endpoints (% correct preferential diagnoses, n differential diagnoses within correct preferential diagnosis) and subgroup analyses (asthma, COPD, interstitial lung disease and no primary pulmonary abnormality) will be evaluated not only considering final diagnosis as standard but als correct side diagnosis

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026